Immune OrganoHub Organoid Drug Efficacy Assessment Platform
In 2025, the FDA announced its plan to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs, encouraging the use of emerging technologies such as AI-driven computational models, organoids, and organ-on-a-chip systems as viable alternatives. Meanwhile, China’s “14th Five-Year” Plan also strategically promotes the development of organoid platforms.
The company has established an organoid-based drug efficacy evaluation platform, leveraging patient-derived organoids to closely mimic human physiology and disease states. This innovative approach provides a more efficient and precise in vitro assessment system for drug screening and personalized treatment strategies, significantly accelerating the pace of new drug development.
Platform features:
● Highly simulates the human physiological environment, enhancing the accuracy of drug response predictions
● High-throughput screening significantly reduces R&D costs and timelines.
● Sourced from patient organizations, supporting personalized precision medicine and ethical alternatives
Consultation Hotline
